Sinovac Biotech Ltd (SVA) stock

SVANasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Jun 5, 2026Score 6/30

$6.47+0.00 (0.00%)

Close on Nov 13, 2026Market cap $464.94MP/E –Yield 850.08%

Sinovac Biotech gross margin

Gross margin is gross profit as a percentage of revenue.

For fiscal 2025 it was 67.9%, against 61.1% the year before. The highest annual figure on record is 94.9% in fiscal 2021.

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	67.9%	+6.8
FY2024	Dec 31, 2024	61.1%	−7.7
FY2023	Dec 31, 2023	68.8%	+13.4
FY2022	Dec 31, 2022	55.3%	−39.6
FY2021	Dec 31, 2021	94.9%	+8.0
FY2020	Dec 31, 2020	86.8%	+0.0
FY2019	Dec 31, 2019	86.8%	−2.4
FY2018	Dec 31, 2018	89.2%	+0.8
FY2017	Dec 31, 2017	88.4%	+19.3
FY2016	Dec 31, 2016	69.1%	−3.6
FY2015	Dec 31, 2015	72.7%	−2.7
FY2014	Dec 31, 2014	75.4%	+4.0
FY2013	Dec 31, 2013	71.4%	+10.2
FY2012	Dec 31, 2012	61.2%	−1.6
FY2011	Dec 31, 2011	62.8%	+12.9
FY2010	Dec 31, 2010	49.9%	−26.2
FY2009	Dec 31, 2009	76.2%	–

Parsed from the XBRL in Sinovac Biotech's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SVA.

Revenue growth6.8% · median -2.1%

Gross margin67.9% · median 54.7%

Operating margin-127.0% · median -42.1%

Advertisement
300 × 250

See a number that looks wrong?